NASDAQ · PBLS

Parabilis Medicines, Inc.

$31.28 -$1.53 (-4.66%) 1D Market open
Charting by TradingView

Key Metrics

$4.01B
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM —
Dividend yield —
Free cash flow —
Beta · 1Y —
EBITDA · TTM —
Gross margin —

Snapshot

Market cap$4.01B
Enterprise value—
Shares outstanding122.3M
52-wk range$24.51 – $34.47
Avg volume · 20D909.9K
Net cash —
Book value / share—
ExchangeNASDAQ
About Parabilis Medicines, Inc.
IPO dateJun 10, 2026
Employees—

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net —
FCF —
ROE / ROIC — · —

Financial Health

Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital—

Cash Flow · TTM

Operating CF —
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

—
Needs two fiscal years of filings

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value